Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P Jr, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Owonikoko TK, et al. Among authors: hirsch fr. Clin Lung Cancer. 2021 May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10. Clin Lung Cancer. 2021. PMID: 33583720 Free PMC article. Clinical Trial.
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR; Southwest Oncology Group. Hirsch FR, et al. J Clin Oncol. 2005 Oct 1;23(28):6838-45. doi: 10.1200/JCO.2005.01.2823. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998906 Clinical Trial.
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr. Hirsch FR, et al. Ann Oncol. 2007 Apr;18(4):752-60. doi: 10.1093/annonc/mdm003. Epub 2007 Feb 22. Ann Oncol. 2007. PMID: 17317677 Free article.
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA Jr, Franklin WA. Hirsch FR, et al. Cancer. 2008 Mar 1;112(5):1114-21. doi: 10.1002/cncr.23282. Cancer. 2008. PMID: 18219661 Free PMC article. Clinical Trial.
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Hesketh PJ, et al. Among authors: hirsch fr. J Thorac Oncol. 2008 Sep;3(9):1026-31. doi: 10.1097/JTO.0b013e318183aa1f. J Thorac Oncol. 2008. PMID: 18758306 Free PMC article. Clinical Trial.
Patient selection criteria and the FLEX Study.
Herbst RS, Hirsch FR. Herbst RS, et al. Among authors: hirsch fr. Lancet. 2009 May 2;373(9674):1497-8. doi: 10.1016/S0140-6736(09)60834-5. Lancet. 2009. PMID: 19410696 No abstract available.
461 results